Smartox Biotechnology

Founded in 2011 and based in Grenoble, France, Smartox Biotechnology operates at the intersection of neuroscience, small molecules, and drug delivery by mining animal venoms for therapeutic peptides. The company has a dual business model, providing both research tools (a catalog of toxins and custom synthesis services) and drug discovery services (its VenomScreen library and hit-to-lead programs) to pharmaceutical and academic partners. As a private company, it appears to be in an early revenue stage, commercializing its platform while potentially advancing internal or partnered discovery programs. Its core value proposition is turning the complex molecular diversity of venoms into validated starting points for novel drug candidates.

Integrated venomics platform for sourcing, screening, and synthesizing bioactive peptide toxins from animal venoms. Includes a curated screening library (VenomScreen) and hit-to-lead services for drug discovery.

Smartox competes with other venom/biologics discovery firms (e.g., Centrose, Vivencia Bio), general peptide CROs/CDMOs, and large contract research organizations offering screening services. Its differentiation lies in its deep specialization in venom peptides, integrated platform from sourcing to synthesis, and focus on neuroscience targets.